A new immune-modulating treatment has shown promising results for treating moderate to severe eczema, delivering fast itch ...

Despite Nektar’s share price shooting up as much as 175% on Tuesday, William Blair maintained that “there is an absence of ...

[A]lthough our findings found that there is insufficient evidence to suggest that dupilumab use is associated with joint pain, the prevalence of joint pain observed among patients treated with ...

Nektar Therapeutics NKTR announced that the phase IIb REZOLVE-AD study evaluating its lead pipeline candidate, ...

NKTR stock is up around 150% in today’s trading session following the recently announced positive results from its Phase 2b ...

The data showed strong efficacy across multiple endpoints and consistent safety, reinforcing confidence in ...

Nektar Therapeutics shares doubled in early trading Tuesday after the U.S. biotech firm said it reached its targets in a ...

Ambient air pollution, hot and cold temperature extremes and other factors associated with climate change are likely ...

A new study published in the Journal of American Medical Association showed that dupilumab (Dupixent), used for treating ...

Nektar reported positive Phase 2b trial data for rezpegaldesleukin in atopic dermatitis, showing strong efficacy and a ...

The Food and Drug Administration in February granted fast track designation for rezpegaldesleukin to treat adults and pediatric patients 12 years and up with moderate to severe atopic dermatitis, the ...